Generic Actos producers avoid pay-for-delay suit


Five generic drug companies, along with Takeda, have avoided a pay-for-delay suit in regards to Takeda’s diabetes drug Actos. US District Judge Ronnie Abrams ruled in favor of the defendants, who claimed that the patent litigation settlements between Takeda and the generic drug producers should not be subject to anti-trust scrutiny by regulators. Judge Abrams ruled that Takeda simply provided early-entry licenses to the generics companies–not any financial payments for not entering the market with a generic version of Actos. Judge Abrams dismissed the case with prejudice, having said that the plaintiffs already amended their complaint three times and any additional complaint would likely be futile.


Read the source article at Law 360

About the Author

Related Posts

Leave a Reply